Angvaccine (HJY-ATRQβ-001)
/ Wuhan Huajiyuan Biotechnology
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
October 16, 2026
A Randomized, Double-blind, Placebo-Controlled Phase I Clinical Trial of the Safety and Tolerability of a Single Administration and dose escalation of Angiotensin II Receptor Type 1 Therapeutic Antihypertensive Vaccine in Healthy Subjects (TAVAR-1)
(ChiCTR)
- P=N/A | N=50 | Recruiting | Sponsor: Union hospital of Tongji Medical College, Huazhong University of Science and Technology; Union hospital of Tongji Medical College, Huazhong University
New trial • Cardiovascular • Hypertension
1 to 1
Of
1
Go to page
1